One of the quiet sources of uncertainty in day-to-day practice is what to do when your Trust's local guideline says one thing and NICE says another. It happens more often than people expect, particularly with antibiotics, and the answer is not simply "national trumps local" or the reverse. Both exist for good reasons, and knowing which governs which situation, and when to escalate, is a core clinical skill. Here is a practical guide to national versus local guidance at the point of care, why antimicrobial prescribing is the clearest example, and how to handle a genuine conflict.
In brief: In UK clinical practice, local guidelines usually govern how care is delivered within a Trust or ICB, while NICE and national guidance provide the broader evidence-based standard. Where they differ, clinicians should understand why, follow local governance where appropriate, and escalate uncertainty when patient-specific factors make the pathway unsafe.
Key takeaways
- National guidance, such as NICE, sets the evidence-based standard and the wider clinical reasoning.
- Local guidelines reflect formulary, resistance patterns, available services, referral pathways and governance.
- For delivery of care within a Trust or ICB, local guidance usually governs, and often for good reason.
- Antimicrobial prescribing is the clearest case where local guidance deliberately differs from national.
- When patient-specific factors make a pathway unsafe, follow judgement and escalate, documenting your reasoning.
What national guidance provides
National guidance, principally NICE, along with NICE CKS, SIGN and national drug references such as the BNF, sets the evidence-based baseline: what the best available evidence supports for diagnosis, management and prescribing across the population. It is rigorous, regularly updated, and the standard against which practice is generally judged, and it carries the clinical reasoning that explains why a recommendation exists. What it cannot do is account for every local factor, because it is written for the whole country rather than your specific hospital, formulary or population. So national guidance tells you what the evidence supports in general, which is essential, but not always the whole answer for how care is delivered where you work.
What local guidance provides
Local guidelines translate national standards into how care actually runs in your organisation. They reflect the local formulary and which drugs are stocked and funded, local antimicrobial resistance patterns, the services and investigations actually available, agreed referral pathways, and local governance and safety priorities. This is why a local guideline may specify a particular first-line agent, a particular referral route, or a particular threshold that differs from a national summary: it is tailored to what is safe, available and appropriate in that setting. Following local guidance is usually the safe default for delivering care, because it encodes decisions your organisation has made deliberately, and because it is what your governance holds you to.
Why antimicrobial prescribing is the clearest example
Antibiotics are where the national-versus-local distinction is most visible and most consequential. Local antimicrobial guidelines are deliberately shaped by local resistance data and stewardship goals, and they sometimes depart from national guidance on purpose. Some Trusts, for instance, restrict agents such as cephalosporins, fluoroquinolones and co-amoxiclav to reduce Clostridioides difficile and resistant organisms, so their empirical choices differ from what a national guideline might suggest. In this domain, local policy takes precedence for empirical treatment, precisely because it reflects local epidemiology that national guidance cannot. It is the canonical example of local guidance legitimately overriding national guidance, and it is why every hospital maintains its own antibiotic policy.
When local guidance may legitimately differ
Beyond antimicrobials, local guidance can reasonably differ from national for several sound reasons: the local formulary does not stock a nationally suggested drug, a service or investigation assumed by national guidance is not locally available, local resistance or population factors change the calculus, or capacity and pathway realities require a different route. These are not failures to follow evidence; they are legitimate local adaptations of it. The key is that a difference should be intentional and governed, not accidental, and where it exists, the local pathway is usually the one to follow for delivering care in that organisation.
Handling a genuine conflict, and when to escalate
Sometimes following the pathway is not safe for the patient in front of you, and that is where judgement takes over from both guidelines. If a patient's specific circumstances, an allergy, a comorbidity, renal impairment, a contraindication, or an atypical presentation, make the local pathway unsafe or inappropriate, the right move is not to follow it blindly but to reason it through, seek senior or specialist input, and document your rationale. Escalation is not a failure; it is the correct response to a situation neither guideline fully covers. The principle is: follow local governance where appropriate, understand why national and local differ, and escalate and document when patient-specific factors make the pathway unsafe.
Where each tool fits
The two kinds of guidance are now delivered by different tools, and it helps to be clear about which does what. A local platform, such as Eolas, which many Trusts now use for antimicrobial and other local guidelines, is where you find the local rule for your organisation. A national reference and reasoning layer is where you understand the evidence and reason through the patient. iatroX sits in the latter: Ask iatroX answers grounded in NICE, CKS, SIGN and the SmPC, with the source attached, so you can check the national standard, reason around contraindications and monitoring, and learn from the case, as a free, UKCA-marked, MHRA-registered clinical tool. Use the local platform for the local rule and iatroX for the evidence and reasoning. Try it at Ask iatroX, and for how local antimicrobial guidance now reaches you, see MicroGuide moving to Eolas.
Frequently asked questions
Should I follow local guidelines or NICE? For delivering care within a Trust or ICB, local guidelines usually govern, because they reflect formulary, resistance, available services and governance. NICE provides the evidence-based standard. Where they differ, understand why, follow local governance where appropriate, and escalate when patient-specific factors make the pathway unsafe.
Why do local antibiotic guidelines differ from national ones? Because they are tailored to local resistance patterns and stewardship goals. Some Trusts restrict certain antibiotics to reduce C. difficile and resistant organisms, so their empirical choices differ from national guidance. For empirical antimicrobial treatment, local policy takes precedence.
Is it wrong for a local guideline to depart from NICE? Not if it is intentional and governed. Local guidance legitimately adapts national standards to formulary, available services, resistance and capacity. A departure should be deliberate and documented, not accidental, and the local pathway usually governs care delivery.
What if the local pathway is unsafe for my patient? Do not follow it blindly. If specific factors such as an allergy, comorbidity or contraindication make it unsafe, reason it through, seek senior or specialist input, and document your rationale. Escalation is the correct response when neither guideline fully fits.
Which tools help with local versus national guidance? A local platform such as Eolas is where you find your Trust's local rule. A national reference and reasoning tool such as Ask iatroX, grounded in NICE, CKS, SIGN and the SmPC, is where you check the evidence standard and reason through the patient. Use both for their respective jobs.